About Bipolar Disorder Therapeutic
Bipolar disorder, also called manic-depressive disorder, is a mental disorder that causes unusual mood swings in patients. The disease causes periods of depression and mania in patients.
Technavio’s analysts forecast the global bipolar disorder therapeutic market to grow at a CAGR of 2.22% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global bipolar disorder therapeutic market for 2017-2021. To calculate the market size, the report considers the sales of drugs in the bipolar disorder therapeutic market.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Bipolar Disorder Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Eli Lilly
• Bristol-Myers Squibb
• AstraZeneca
Other prominent vendors
• Allergan
• Astellas Pharma
• GlaxoSmithKline
• Janssen Pharmaceuticals
Market driver
• Need to reduce financial burden of bipolar disorder
• For a full, detailed list, view our report
Market challenge
• Lack of adequate diagnostic process
• For a full, detailed list, view our report
Market trend
• Awareness about bipolar disorder in children (pediatric extension)
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Key market highlights
PART 05: Disease overview
PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 07: Pipeline landscape
PART 08: Market segmentation by drug class
• Market overview
• Antipsychotics
• Anticonvulsants
• Traditional mood stabilizers
• Others
PART 09: Geographical segmentation
• Bipolar disorder therapeutics market in Americas
• Bipolar disorder therapeutic market in EMEA
• Bipolar disorder therapeutic market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
• Market drivers
• Impact of drivers on key customer segments
• Market challenges
• Impact of challenges on key customer segments
PART 12: Market trends
• Awareness about bipolar disorder in children (pediatric extension)
• Rising application of combination therapies
PART 13: Vendor landscape
• Competitive scenario
PART 14: Key vendor analysis
• Eli Lilly
• Bristol-Myers Squibb
• AstraZeneca
• Other prominent vendors
PART 15: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Different types of bipolar disorder
Exhibit 02: Factors causing bipolar disorder
Exhibit 03: Medication guidelines for managing bipolar disorder
Exhibit 04: Global bipolar disorder therapeutics market: Snapshot
Exhibit 05: Global bipolar disorder therapeutic market 2016-2021($ millions)
Exhibit 06: Global bipolar disorder therapeutic market: Opportunity analysis
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline snapshot
Exhibit 09: Pipeline landscape
Exhibit 10: Global bipolar disorder therapeutic market by drug class 2016 and 2021
Exhibit 11: Global bipolar disorder therapeutic market by drug class
Exhibit 12: Uses and side-effects of antipsychotics
Exhibit 13: Global bipolar disorder antipsychotics drugs market 2016-2022 ($ millions)
Exhibit 14: Old generation anticonvulsants for bipolar disorder treatment: Snapshot
Exhibit 15: New generation anticonvulsants for bipolar disorder treatment: Snapshot
Exhibit 16: Uses and side-effects of anticonvulsants
Exhibit 17: Global bipolar disorder antipsychotic drug market 2016-2022 ($ millions)
Exhibit 18: Global bipolar disorder traditional mood stabilizers drug market 2016-2022 ($ millions)
Exhibit 19: Global bipolar disorder therapeutic market for other drugs 2016-2022 ($ millions)
Exhibit 20: Global bipolar disorder therapeutic market by geography 2016 and 2021
Exhibit 21: Bipolar disorder therapeutic market by geography 2016-2021 ($ millions)
Exhibit 22: Market scenario in Americas
Exhibit 23: Bipolar disorder therapeutic market in Americas 2016-2021 ($ millions)
Exhibit 24: Market scenario in EMEA
Exhibit 25: Bipolar disorder therapeutic market in EMEA 2016-2021 ($ millions)
Exhibit 26: Market scenario in APAC
Exhibit 27: Bipolar disorder treatment market in APAC 2016-2021 ($ millions)
Exhibit 28: Economic burden of mental illnesses
Exhibit 29: Initiatives for people with mental disorders
Exhibit 30: Impact of drivers
Exhibit 31: Financial loss due to patent issues
Exhibit 32: Major side-effects of bipolar disorder medications
Exhibit 33: Impact of challenges
Exhibit 34: Competitive structure analysis of global bipolar disorder therapeutic market 2016
Exhibit 35: Strategic success factors of companies in global bipolar disorder therapeutic market
Exhibit 36: Eli Lilly: Key highlights
Exhibit 37: Eli Lilly: Strength assessment
Exhibit 38: Eli Lilly: Strategy assessment
Exhibit 39: Eli Lilly: Opportunity assessment
Exhibit 40: Eli Lilly: YoY growth rate of Zyprexa 2014-2015 ($ millions)
Exhibit 41: Bristol-Myers Squibb: Key highlights
Exhibit 42: Bristol-Myers Squibb: Strength assessment
Exhibit 43: Bristol-Myers Squibb: Strategy assessment
Exhibit 44: Bristol-Myers Squibb: Opportunity assessment
Exhibit 45: Bristol-Myers Squibb: Revenue and YoY growth rate of Abilify 2013-2015 ($ millions)
Exhibit 46: AstraZeneca: Key highlights
Exhibit 47: AstraZeneca: Strength assessment
Exhibit 48: AstraZeneca: Strategy assessment
Exhibit 49: AstraZeneca: Opportunity assessment
Exhibit 50: AstraZeneca: Revenue and YoY growth rate of Seroquel 2013-2015 ($ millions)
